John L. Hays, MD, PhD, discusses the evolution of the treatment paradigm for patients with metastatic colorectal cancer who experience disease progression following standard chemotherapy regimens.
John Hays, MD, PhD
Advertisement
Articles by John Hays, MD, PhD
John L. Hays, MD, PhD, discusses the significance of the approval for tucatinib and trastuzumab for patients with HER2-expressing metastatic colorectal cancer.
John L. Hays, MD, PhD, discusses the evolution of treating patients with hepatocellular carcinoma.
John Hays, MD, PhD, discusses immunotherapy research in gynecologic cancer.
John Hays, MD, PhD, discusses the progression of immunotherapy in treating patients with ovarian cancer.
John Hays, MD, PhD, discusses investigational combinations of PARP inhibitors and immunotherapy in ovarian cancer.
John Hays, MD, PhD, discusses the potential for PARP inhibitor combinations in patients with ovarian cancer.
Advertisement
Latest Updated Articles
Dr. Hays on Potential for PARP Inhibitor Combinations in Ovarian CancerPublished: December 11th 2019 | Updated:
Dr. Hays on Combining PARP Inhibitors With Immunotherapy in Ovarian CancerPublished: December 16th 2019 | Updated:
Dr. Hays on Immunotherapy in Ovarian Cancer TreatmentPublished: January 15th 2020 | Updated:
Dr. Hays on Immunotherapy Research in Gynecologic CancerPublished: February 22nd 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5